Bimoxyl LA

For the control and treatment of respiratory and other infections in cattle caused by amoxicillin susceptible Gram-positive and Gram-negative bacteria only.

Description

Treatment and control of bacterial infections

Active Constituent

Amoxicillin (as trihydrate) 150 mg/mL (equivalent to amoxicillin trihydrate 172 mg)

Indications

For the control and treatment of respiratory and other infections in cattle caused by amoxicillin susceptible Gram-positive and Gram-negative bacteria only.

For the treatment of infectious diseases in pigs and sheep caused by or associated with organisms sensitive to amoxicillin.

Bimoxyl LA has specified indications for each target species (susceptible genus and species of bacteria) as follows;

Cattle: Respiratory tract infections caused by Pasteurella multocida and Mannheimia haemolytica.

Omphalophlebitis, septicaemia and infectious arthritis caused by susceptible isolates of E. coli and Streptococcal spp.

Gastrointestinal infections caused by susceptible isolates of E. coli.

Urogenital tract infections caused by Corynebacterium renale, Streptococcus spp. and Proteus spp. Intramammary infections cause by Arcanobacterium pyogenes, and susceptible isolates of Streptococcus spp., Staphylococcus spp. (non-β lactamase producing) and Escherichia coli.

Soft tissue infections caused by Arcanobacterium pyogenes, Fusobacterium necrophorum and susceptible isolates of Staphylococcus spp. and Streptococcus spp.

Pigs: Respiratory tract infections cause by Pasteurella multocida and Actinobacillus pleuropneumoniae. Septicaemic infections and infectious arthritis caused by Haemophilus parasuis, Actinobacillus suis, Streptococcus spp. and Erysipelas rhusiopathiae.

Urogenital tract infections caused by Actinobaculum (Eubacterium) suis and susceptible isolates of E. coli. MMA syndrome involving susceptible isolates of E. coli or Streptococcus spp.

Soft tissue infections caused by susceptible isolates of Staphylococcus spp. and Streptococcus spp.

Sheep: Respiratory tract infections caused by Pasteurella multocida, Bibersteinia (Pasteurella) trehalosi and Mannheimia haemolytica.

Omphalophlebitis, septicaemia and infectious arthritis caused by Erysipelas rhusiopathiae, Streptococcus dysgalactiae, Fusobacterium, Corynebacterium ovis and susceptible isolates of E. coli and other Streptococcal spp.

Gastrointestinal infections caused by susceptible isolates of E. coli and Salmonella spp. (excluding S.typhimurium).

Contagious foot rot infections caused by Treponema spp., Fusobacterium necrophorum and non-β lactamase producing Dichelobacter nodosus.

Dosage and Administration

For intramuscular (IM) injection only.

The recommended dosage rate is 15 mg amoxicillin/kg bodyweight, equivalent to 1 mL/10kg bodyweight.

To ensure dosage, bodyweight should be determined as accurately as possible to avoid under dosing.

If the dose volume exceeds 20mL (cattle), 5mL (pigs), 4mL (sheep), the dose should be divided and administered at two separate sites.

Repeat after 48 hours if necessary. Separate site(s) to the first injection(s) must be used.

Injection to be given into the anterior half of the neck. The injection site should be massaged after injection.

Use a dry, sterile needle and syringe for extraction of suspension to avoid hydrolysis of amoxicillin.

Contraindications

Not suitable for intravenous (IV) or intrathecal administration.

Not to be used in ewes producing milk for human consumption.

Not to be administered to rabbits, hamsters, guinea pigs, gerbils or any other small herbivores.

Do not use in cases of known hypersensitivity to amoxicillin or penicillins.

Precautions for use

Use of the product should be based on susceptibility testing of the bacteria isolated from the animal. If this is not possible, therapy should be based on local (regional, farm level) epidemiological information about susceptibility of the target bacteria.

Use of the product deviating from the indications for use and dosage information may increase the prevalence of bacteria resistant to amoxicillin and may decrease the effectiveness of treatment with other penicillins due to the potential for cross-resistance.

Side-effects

Occasional local reaction of a transient nature may occur at the site of injection.

Interaction with other medicinal products and other forms of interaction

Beta-lactam antibiotics are known to interact with antibiotics with bacteriostatic action such as chloramphenicol, macrolides, sulphonamides and tetracyclines. There is also synergic action of penicillins with aminoglycosides.

Withdrawal Periods

Milk (Cattle): Milk intended for sale for human consumption must be discarded treatment and for 72 hours following the last treatment.

Milk (Sheep): Milk intended for sale for human consumption must be discarded during treatment and 35 days following the last treatment.

Meat: Animals producing meat and offal for human consumption must not be sold for slaughter either during treatment or within: –

Cattle: 14 days from the last treatment.

Sheep: 14 days from the last treatment.

Pigs: 10 days from the last treatment.

Storage

Store below 25°C. Protect from light. Shake well before use. This product does not contain an antimicrobial preservative.

Other Information

Swab the septum before removing each dose. Use a dry sterile needle and syringe. Following the withdrawal of the first dose, use the product within 4 weeks. Dispose of unused material safely. Keep out of reach of children.

Presentation

Available 100mL glass vials

ACVM Registration Number

Registered pursuant to the ACVM Act 1997, No. A7057

See www.foodsafety.govt.nz for registration conditions

Bimoxyl LA

Bimoxyl LA

In stock

For the control and treatment of respiratory and other infections in cattle caused by amoxicillin susceptible Gram-positive and Gram-negative bacteria only.

SKU: BIMO01